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INTRODUCTION
Oncologists subcategorize breast cancer patients into those 
that are hormone-receptor positive, HER2-positive, or both 
hormone-receptor and HER2-negative, and treatment varies 
with subcategory. Triple receptor-negative (TRN) breast can-
cer is a subcategory that lacks expression of estrogen receptors 
(ER-), progesterone receptors (PR-), and human epidermal 
growth factor receptor 2 (HER2-) [1-4]. This subtype, which 
comprises 15% of all breast cancers [5], currently lacks effec-
tive targeted therapies. TRN breast cancers are typically char-
acterized by large, high-grade tumors that have relatively high 
rates of recurrence and distant metastasis, and low overall sur-
vival rates [4,6-8]. TRN breast cancers are not identical to bas-
al-like breast cancers, but have similar clinical and pathologi-
cal features. Both types of breast cancer are associated with poor 
overall prognosis and response to chemotherapy, such as an-
thracycline- and taxane-based regimens [3,5,6,9,10]. 
Cohort studies have shown that TRN breast cancers occur 
at high frequencies in relatively young women and in African 
American women [1,2,7,11]. In Asia, TRN breast cancers oc-
cur at rates similar to those reported for Western countries [12], 
and are often characterized by young age of onset and dense 
breast tissues. 
The incidence of breast cancer in Korea has been increasing 
over time, and is characterized by a young age of onset in com-
parison to Western countries [13-15]. Molecular profiling has 
revealed that Korean women are more likely to have the aggres-
sive basal cell type of breast cancer than TRN breast cancer, 
which may account for worse prognoses of Korean women, 
compared to young women of European descent [15,16]. How-
ever, data specifically concerning phenotypes of TRN breast 
cancer in Korea are very limited. Furthermore, only a few pre-
vious reports have described the imaging features of TRN breast 
cancers [17,18]. The goals of the present study were to describe 
the TRN phenotypes of Korean breast cancer patients and to 
evaluate high-resolution ultrasound (HR-US) imaging features 
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Purpose: Triple receptor-negative (TRN) breast cancer is associ-
ated with high risk of recurrence and poor prognosis. The pre- 
sent study assessed the clinicopathologic characteristics and ul-
trasound (US) features of TRN breast cancers. Methods: Pathol- 
ogical and biological data were reviewed for 558 breast cancer 
patients treated at Kangbuk Samsung Hospital, between Janu-
ary 2003 and December 2009. The patients were separated into 
TRN breast cancer and non-TRN breast cancer groups, based 
on the results of immunohistochemical prognostic panels. Clini-
cal and pathologic features were compared for the two groups. 
US features, including shape, orientation, margins, boundaries, 
echo patterns, posterior acoustic features, surrounding tissues, 
and microcalcifications, were determined for 41 TRN patients and 
189 non-TRN controls (ER+/PR+/HER2-). Results: Of 558 cases, 
58 (10.4%) had the TRN phenotype. Four hundred and thirty-four 
cases (77.8%) were invasive ductal carcinomas. TRN cancer was 
significantly associated with specific characteristics of tumor size, 
nuclear grade, histologic grade, venous invasion, and lymphatic 
invasion. With respect to US features, TRN cancers were more 
likely to have an oval shape, a circumscribed margin, and marked 
hypoechogenicity.  Conclusion: Tumor characteristics were differ-
ent between TRN and non-TRN breast cancers, although US can-
not differentiate the subtype of breast cancers TRN cancer tend 
to show somewhat different US morphology.
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that could be used to discriminate TRN breast cancers from 
non-TRN breast cancers.  
METHODS
Patient selection 
This retrospective study consisted of 622 consecutive patients 
who had surgery for breast cancer at Kangbuk Samsung Hos-
pital between March 2003 and December 2009, 467 underwent 
modified radical mastectomy (MRM), 65 underwent either 
partial mastectomy or quadrantectomy, and 26 underwent 
lumpectomy (BCS) or wide excision. Of the 622 total patients, 
485 underwent axillary dissection, and 73 underwent sentinel 
lymph node dissections. Of the total patients, 558 underwent 
HR-US breast examination within one month prior to surgery. 
Ten patients that presented with bilateral breast cancer (n = 10), 
and 54 who had not undergone preoperative assessment or 
immunohistochemical tests for ER, PR, HER2, were excluded 
from the image evaluations. The age range of the 588 patients 
was 24-88 years, and the mean age was 49.8 years. Patients who 
were examined from screening center were not included in this 
study. 
Clinical pathology
All TRN and non-TRN patients were examined for the type 
of pathology, tumor size, nuclear grade, histologic grade, venous 
invasion, lymphatic invasion, lymph node metastasis, associ-
ated ductal carcinomas in situ (DCIS), distant metastasis state, 
and recurrence. The tumor grades of invasive carcinomas were 
classified as grade 1 (low), grade 2 (moderate), or grade 3 (high) 
based on the frequency of cell mitosis, tubule formation, and 
nuclear pleomorphism. DCIS cases were divided into grade 1 
(low), grade 2 (moderate), or grade 3 (high) based on nuclear 
grade, architecture, and necrosis. 
Immunohistochemistry and fluorescence in situ hybridiza-
tion (FISH) performed on breast tissue specimens were used 
to evaluate ER, PR, and HER-2/neu status. Immunohistochem-
istry was performed for all breast carcinomas. Overexpression 
of the HER-2/neu gene (HER2+) was defined as level 3 staining 
intensity. Carcinomas with 0 or 1 staining intensity were con-
sidered negative for overexpression. Carcinomas with level 2 
staining intensity were defined as indeterminate, and HER-2/
neu overexpression was then evaluated by FISH. Based on re-
sults of the analyses, 58 of the 558 patients (10.4%) were clas-
sified as TRN, and 500 (89.6%) were classified as non-TRN. 
HR-US evaluations
HR-US features were analyzed for 41 TRN patients and 189 
non-TRN patients, who were ER+/PR+/HER2-. In each case, 
one of three board-certified breast radiologists, with 5-20 years 
of experience in breast US, performed a preoperative HR-US 
examination of the breast lesion, using an HDI 5000 unit (ATL, 
Bothell, USA) or an IU-22 (Philips Medical Systems, Best, The 
Netherlands) and a 12-5 MHz linear-array transducer. Imag-
ing data were analyzed retrospectively: images from more than 
two different planes per lesion were saved as a bitmap file, and 
a radiologist blinded to the immunophenotypes analyzed the 
images according to the Breast Imaging Reporting and Data 
System (BI-RADS) lexicon. Tumor shape (oval, round, irregu-
lar), orientation (parallel, not parallel), margins (circumscribed, 
indistinct, angular, microlobulated, spiculated), boundaries 
(abrupt interface, echogenic halo), echo patterns (hypoechoic, 
complex, markedly hypoechoic), posterior acoustic features 
(none, enhancement, shadowing), surrounding tissues (duct 
changes, Cooper’s ligament changes or architectural distortion, 
skin thickening or edema), and microcalcifications were eval-
uated.
 Statistical analyses
The chi-squared test or Fisher exact test was used to compare 
parameters for TRN and non-TRN patients. Student’s t-test 
and Mann-Whitney U-test were used. The normal distribu-
tion of data in each group was confirmed with a Kolmogorov-
Smirnov test before the t-test was run. A two-tailed p<0.05 
indicated a significant difference between groups. Data analy-
ses were performed with SPSS for Windows, version 16.0 (SPSS 
Inc., Chicago, USA).
RESULTS
Of the 558 breast tumors examined, there were 434 (77.8%) 
invasive ductal carcinomas, 72 DCIS, 16 mucinous carcinomas, 
10 invasive lobular carcinomas, 7 microinvasive carcinomas, 3 
papillary carcinomas, 3 medullary carcinomas, 3 mixed ductal 
and lobular carcinomas, 2 metaplastic carcinomas, 2 tubular 
carcinomas, 2 invasive cribriform carcinomas, 2 invasive mi-
cropapillary carcinomas, 1 acinic cell carcinoma, and 1 apo-
crine carcinoma. 
The 58 patients in the TRN group had a mean age of 48 years 
(range, 30-82 years), and the 500 patients in the non-TRN group 
had a mean age of 50 years (range, 24-88 years). There was no 
significant difference between the two groups in the percent-
age of patients <40 years (Table 1). Tumors <1 cm were signif-
icantly less frequent in the TRN group than in the non-TRN 
group, while the opposite was true for tumors >2 cm. 
Tumors with high histologic and nuclear grades were signif-
icantly more prevalent in the TRN group than in the non-TRN 
group (Table 1). The frequencies of venous and lymphatic in-TripleReceptor-NegativeBreastCancers 121
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vasion were also significantly higher in TRN patients than in 
non-TRN patients. However, the frequencies of a positive re-
section margin, lymph node metastasis, microcalcifications, 
associated DCIS, distant metastasis, and recurrence did not 
differ significantly between the two groups.
HR-US evaluations showed that TRN cancers were more like-
ly to have an oval shape or circumscribed margin, were more 
markedly hypoechoic and less likely to have posterior shadow-
ing than non-TRN cancers (e.g., Table 2). The other HR-US 
features did not differ significantly between the TRN and non-
TRN groups.
DISCUSSION
Results of the present study found some pathologic features 
that was different between TRN from non-TRN tumors: tumor 
size was significantly larger, nuclear and histologic grades were 
significantly higher, venous and lymphatic invasion were sig-
nificantly more common in the TRN group than in the non-
TRN group. However, previous clinical studies found that over-
expression of the HER-2/neu gene (HER2+) is associated with 
some of the same pathologic features, including large tumor 
size, axillary lymph node metastasis, negative hormone recep-
Table 2. Comparison of ultrasound features of TRN and non-TRN tu-
mors
US features
TRN  
(n=41)  
No. (%)
Non-TRN 
(n=189)  
No. (%)
p-value
Shape
   Oval
   Round
   Irregular
 
15 (36.6)
2 (4.9)
24 (58.5)
 
  34 (18.0)
15 (7.9)
140 (74.1)
0.030
Orientation
   Parallel
   Not parallel
 
22 (53.7)
19 (46.3)
 
  74 (39.2)
115 (60.8)
NS
Margin
   Circumscribed
   Indistinct, angular, 
      microlobulated
   Spiculated 
 
  9 (22.0)
11 (26.8)
21 (51.2)
 
16 (8.5)
  58 (30.7)
115 (60.8)
0.042
Lesion boundary
   Abrupt interface
   Echogenic halo
 
19 (46.3)
22 (53.7)
 
  78 (41.3)
111 (58.7)
NS
Echo pattern
   Hypoechoic
   Complex
   Markedly hypoechoic
 
17 (41.5)
20 (48.8)
4 (9.8)
 
131 (69.3)
  57 (30.2)
  1 (0.5)
NS
Posterior features
   No posterior
   Enhancement
   Shadowing
 
30 (73.2)
  7 (17.1)
4 (9.8)
 
127 (67.2)
16 (8.5)
  46 (24.3)
0.051
Surrounding tissue change
   Negative 
   Duct changes
   Architectural distortion, 
      Cooper’s ligament change
   Skin thickening, edema
  
17 (41.5)
  6 (14.6)
15 (36.6)
 
3 (7.3)
  
  64 (33.9)
  48 (25.4)
  76 (40.2)
 
  1 (0.5)
NS
Microcalcification
   No
   Yes
 
32 (78.0)
  9 (22.0)
 
143 (75.7)
  46 (24.3)
NS
Assessment category
   C3 (probably benign)
   C4 (suspicious)
   C5 (highly suggestive)
 
2 (4.9)
15 (36.6)
24 (58.5)
 
  3 (1.6)
  64 (33.9)
122 (64.6)
NS
TRN=triple receptor negative; US=ultrasound; NS=not significant.
Table 1. Pathologic features of TRN and non-TRN breast cancer
Parameters
TRN  
(n=58)
Non-TRN 
(n=500)
p- 
value
No. (%)
No. of 
avail-
able 
cases
No. (%)
No. of 
avail-
able 
cases
Age (yr)
   <40
   ≥40
 
11 (19.0)
47 (81.0)
 
  56 (11.2)
444 (88.8)
NS
Size (cm)
   <1
   ≥1, <2 
   ≥2, <5 
   ≥5 
 
3 (5.2)
20 (34.5)
29 (50.0)
  6 (10.3)
 
104 (20.8)
176 (35.2)
193 (38.6)
27 (5.4)
0.015
Nuclear grade (n=423)*
   I
   II
   III
 
1 (2.3)
15 (34.9)
27 (62.8)
43  
  59 (15.5)
215 (56.6)
106 (27.9)
380 <0.001
Histologic grade (n=477)*
   I
   II
   III
 
3 (5.8)
11 (21.2)
38 (73.1)
52  
120 (28.2)
188 (44.2)
117 (27.5)
425 <0.001
Resection margin 
   Negative
   Positive
 
56 (96.6)
2 (3.4)
 
484 (96.8)
16 (3.2)
NS
Venous invasion (n=320)*
   No 
   Yes
 
26 (78.8)
  7 (21.2)
33  
268 (93.4)
19 (6.6)
287 0.010
Lymphatic invasion (n=369)*
   No
   Yes
 
19 (48.7) 
20 (51.3)
39  
221 (67.0)
109 (33.0)
330 0.024
LN metastasis 
   Negative
   Positive
37 (63.8)
21 (36.2)
333 (66.6)
167 (33.4)
NS
Microcalcifications (n=314)*
   No
   Yes
 
13 (50.0)
13 (50.0)
26  
117 (40.6)
171 (59.4)
228 NS
Associated DCIS  
   No
   Yes
 
50 (86.2)
  8 (13.8)
 
432 (86.4)
  68 (13.6)
NS
Distant metastasis (n=342)*
   No
   Yes
37 (88.1)
  5 (11.9)
42  
272 (90.7)
28 (9.3)
300 NS
Recurrence (n=337)*
   No
   Yes
 
39 (97.5)
1 (2.5)
40  
290 (97.6)
  7 (2.4)
297 NS
TRN=triple receptor negative; LN=lymph node; DCIS=ductal cancer 
in situ; NS=not significant.
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tors, and high tumor grade [6,16]. Although these characteris-
tics suggest poor prognoses, the limited data on treatment re-
sponses and survival of women with TRN breast cancer make 
it difficult to conclude that the factors do contribute to lower 
survival rates. 
We cannot differentiate TRN breast cancers based on US 
imaging but it is important that the radiologist will be aware 
of such subtypes and that radiologist anticipate thorough pre-
operative examination for multifocal breast cancers, or contra-
lateral breast cancer and associated axillary lymph node me-
tastasis or distant metastasis. By comparing HR-US features in 
TRN and ER+/PR+/HER2- patients, the present study found 
imaging differences that may be useful for identifying TRN 
breast cancers but was not specific of the subtype. In this study 
we noticed that many TRN breast cancers, due to their oval 
shape, circumscribed margins, and low echogenicity, the TRN 
tumors resembled benign nodules more closely than the non-
TRN tumors did (Figure 1). These features of TRN tumors may 
lead a radiologist to conclude that the lesion is probably be-
nign, and have the patient wait six months before a follow-up 
US exam or US-guided biopsy. Furthermore, a prior study re-
ported that ER-/PR-/HER2+ breast cancers are commonly as-
sociated with some of the same features as the TRN cancers in 
the present study, specifically calcifications (79%), circumscribed 
margins (57%), markedly low echogenicity (57%), and lack of 
posterior shadowing (5%), and are sometimes depicted as non-
mass lesions (32%) [19]. Although, a tumor with an oval shape, 
a fairly well circumscribed margin, and low echogenicity could 
be confused with a cystic mass, results of the present study in-
dicate that TRN breast cancer should be suspected when the 
tumor has those US features and is also large, palpable, and ex-
hibits rapid growth. Biopsy should be recommended for such 
nodules, even if the echogenicity is not extremely low.  
Results of the present study found a high incidence of mi-
crocalcifications in TRN and non-TRN groups, both of which 
were HER2-negative. However, Wang et al. [18] found that 
ER-/HER2+ breast cancers were more likely to be associated 
with calcifications than TRN cancers. Another previous study 
found that 75% of HER2+ carcinomas were associated with cal-
cifications [16,20]. We analyzed the incidence of DCIS in the 
TRN and non-TRN groups, because microcalcifications previ-
ously found in TRN patients during mammography may have 
been psamomma bodies associated with DCIS. However, we 
did not find a significant association between TRN and DCIS.  
The present study had several limitations. First, identification 
of TRN tumors was predominantly based on immunohisto-
chemical results, and FISH analysis was only used in a limited 
number of cases. FISH analysis provides a more accurate deter-
mination of HER2+, due to false positives in weakly positive 
immunohistochemical results [21-23]. Another limitation was 
that the imaging analyses were limited to malignant nodules, 
which may have influenced interpretation by the radiologists. 
Third, the non-TRN group was limited to ER+/PR+/HER2- 
patients, because based on our experience, most young breast 
cancer patients are HER2-. 
Although results of the present study indicate that it may be 
possible to differentiate TRN cancers from non-TRN cancers 
on the basis of specific US features, further research is needed 
to confirm our findings and to provide a more reliable “alarm” 
for cancers with very poor prognoses.
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